Fresenius SE & Co KGaA 2018 AR2
The report highlights a successful fiscal year 2018 for Fresenius, achieving record sales of ’33,530 million and net income of ’1,871 million before special items. The company proposed its 26th consecutive dividend increase, reflecting its stable business model. Key developments included the termination of the Akorn merger agreement due to data integrity breaches and the transfer of the German post-acute care business from Fresenius Helios to Fresenius Vamed. Additionally, Fresenius Medical Care launched the 4008A dialysis machine tailored for emerging markets and expanded its clinical network to over 3,900 clinics.
Company: Fresenius SE & Co KGaA
Sector: Manufacturing
Country: Germany
Year: 2018
Type: AR2
Pages: 281
Back to company
Fresenius SE & Co KGaA
Annual Report
The report highlights a successful fiscal year 2018 for Fresenius, achieving record sales of ’33,530 million and net income of ’1,871 million before special items. The company proposed its 26th consecutive dividend increase, reflecting its stable business model. Key developments included the termination of the Akorn merger agreement due to data integrity breaches and the transfer of the German post-acute care business from Fresenius Helios to Fresenius Vamed. Additionally, Fresenius Medical Care launched the 4008A dialysis machine tailored for emerging markets and expanded its clinical network to over 3,900 clinics.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Women in Management
Employees